Akari Therapeutics PLC (AKTX)
1.30
+0.06
(+4.84%)
USD |
NASDAQ |
Nov 22, 16:00
1.30
0.00 (0.00%)
After-Hours: 20:00
Akari Therapeutics Cash from Investing (Quarterly)
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2018 | 0.3791M |
| September 30, 2018 | -0.3791M |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 9.991M |
| March 31, 2017 | -0.0056M |
| December 31, 2016 | 35.08M |
| September 30, 2016 | 1.019M |
| Date | Value |
|---|---|
| June 30, 2016 | -46.13M |
| March 31, 2016 | -0.0421M |
| December 31, 2015 | -0.0188M |
| September 30, 2015 | 1.411M |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.142M |
| June 30, 2014 | -0.142M |
| March 31, 2014 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| DBV Technologies SA | -0.109M |
| Ascendis Pharma AS | -- |
| Cellectis SA | 22.33M |
| Adaptimmune Therapeutics PLC | -66.02M |
| Biodexa Pharmaceuticals PLC | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.49M |
| Cash from Financing (Quarterly) | -0.443M |
| Free Cash Flow | -14.84M |
| Free Cash Flow Per Share (Quarterly) | -0.1222 |
| Free Cash Flow Yield | -139.5% |